Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Methylene blue administration in patients with refractory distributive shock - a retrospective study

M. Porizka, P. Kopecky, H. Dvorakova, J. Kunstyr, M. Lips, P. Michalek, M. Balik,

. 2020 ; 10 (1) : 1828. [pub] 20200204

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Hemodynamic effectiveness of methylene blue (MB) was tested in patients with refractory distributive shock. A retrospective analysis of 20 critically-ill patients who developed refractory shock was performed. Patients were divided into two study groups as responders with positive hemodynamic response to MB administration (defined as 10% decrease of norepinephrine dose) and non-responders. Hemodynamic, outcome data and baseline tissue hypoxia-related parameters including ratio of central venous-to-arterial carbon dioxide tension to arterio-venous oxygen content (P(v-a)CO2/C(a-v)O2) were compared between the groups. There were 9 (45%) responders and 11 (55%) non-responders to single bolus of MB administration. Dose of MB did not differ between responders and non-responders (1.3 ± 0.5 vs. 1.3 ± 0.4 mg/kg respectively, P = 0.979). MB responders had lower baseline P(v-a) CO2/C(a-v)O2 (1.79 ± 0.73 vs. 3.24 ± 1.18, P = 0.007), higher pH (7.26 ± 0.11 vs. 7.16 ± 0.10, P = 0.037) and lower lactate levels at 12 hours post MB administration (3.4 ± 2.7 vs. 9.9 ± 2.2 mmol/L, P = 0.002) compared to non-responders. Methylene blue represents a non-adrenergic vasopressor with only limited effectiveness in patients with refractory distributive shock. Profound tissue hypoxia with high degree of anaerobic metabolism was associated with the loss of hemodynamic responsiveness to its administration.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028523
003      
CZ-PrNML
005      
20210114154132.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-020-58828-4 $2 doi
035    __
$a (PubMed)32020043
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Porizka, Michal $u General University Hospital, Department of Anaesthesiology, Resuscitation and Intensive Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. michal.porizka@vfn.cz.
245    10
$a Methylene blue administration in patients with refractory distributive shock - a retrospective study / $c M. Porizka, P. Kopecky, H. Dvorakova, J. Kunstyr, M. Lips, P. Michalek, M. Balik,
520    9_
$a Hemodynamic effectiveness of methylene blue (MB) was tested in patients with refractory distributive shock. A retrospective analysis of 20 critically-ill patients who developed refractory shock was performed. Patients were divided into two study groups as responders with positive hemodynamic response to MB administration (defined as 10% decrease of norepinephrine dose) and non-responders. Hemodynamic, outcome data and baseline tissue hypoxia-related parameters including ratio of central venous-to-arterial carbon dioxide tension to arterio-venous oxygen content (P(v-a)CO2/C(a-v)O2) were compared between the groups. There were 9 (45%) responders and 11 (55%) non-responders to single bolus of MB administration. Dose of MB did not differ between responders and non-responders (1.3 ± 0.5 vs. 1.3 ± 0.4 mg/kg respectively, P = 0.979). MB responders had lower baseline P(v-a) CO2/C(a-v)O2 (1.79 ± 0.73 vs. 3.24 ± 1.18, P = 0.007), higher pH (7.26 ± 0.11 vs. 7.16 ± 0.10, P = 0.037) and lower lactate levels at 12 hours post MB administration (3.4 ± 2.7 vs. 9.9 ± 2.2 mmol/L, P = 0.002) compared to non-responders. Methylene blue represents a non-adrenergic vasopressor with only limited effectiveness in patients with refractory distributive shock. Profound tissue hypoxia with high degree of anaerobic metabolism was associated with the loss of hemodynamic responsiveness to its administration.
650    _2
$a senioři $7 D000368
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hemodynamika $x účinky léků $7 D006439
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methylenová modř $x terapeutické užití $7 D008751
650    _2
$a lidé středního věku $7 D008875
650    _2
$a noradrenalin $x terapeutické užití $7 D009638
650    _2
$a kyslík $x krev $7 D010100
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a šok $x farmakoterapie $x mortalita $7 D012769
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vazokonstriktory $x terapeutické užití $7 D014662
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kopecky, Petr $u General University Hospital, Department of Anaesthesiology, Resuscitation and Intensive Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Dvorakova, Helena $u General University Hospital, Department of Anaesthesiology, Resuscitation and Intensive Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Kunstyr, Jan $u General University Hospital, Department of Anaesthesiology, Resuscitation and Intensive Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Lips, Michal $u General University Hospital, Department of Anaesthesiology, Resuscitation and Intensive Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Michalek, Pavel $u General University Hospital, Department of Anaesthesiology, Resuscitation and Intensive Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Balik, Martin $u General University Hospital, Department of Anaesthesiology, Resuscitation and Intensive Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 1828
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32020043 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154129 $b ABA008
999    __
$a ok $b bmc $g 1608858 $s 1119703
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 1 $d 1828 $e 20200204 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...